In the present analysis of the efficacy of eribulin in an off-trial setting, PFS and OS in patients with heavily pretreated HER2-negative advanced breast cancer were similar to those observed in the phase III EMBRACE trial (4.1 vs 3.7 months and 11.1 vs 13.1 months, respectively) [6–8]. The gene discussed is ERBB2; the disease is breast cancer.